{
  "catalogId": "65dca4df-b9b7-4ef3-845b-8faeb0da608f",
  "name": "BORTEZOMIB TARO 3.5 MG",
  "status": "",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "162 44 35830 00",
  "treatmentDescriptions": "Bortezomib is indicated for the treatment of patients with multiple myeloma.Bortezomib is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",
  "termsOfIssue": "Prescription required",
  "form": "powder for solution for injection",
  "route": "i.v, s.c",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "BORTEZOMIB 3.5 MG/VIAL",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01XX32",
      "name": "BORTEZOMIB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": " ",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "BORTEZOMIB TARO 3.5 MG  PWDR FOR INJ 1VIAL",
      "manufacturer": {
        "name": "תרו יבוא",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "36",
      "storageConditions": "",
      "codes": {
        "moh": "8472",
        "yarpa": "89743",
        "barcode": "7290017164090"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 4020.1981,
        "retailMargin": 10.0,
        "maxRetailPrice": 4422.21791,
        "maxPriceWithVAT": 5218.217134
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T00:40:35.680322"
  }
}